Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial

References

• FerlayJSoerjomataramIErvikM homepage on the InternetGLOBOCAN 2012 – Lung cancer incidence and mortality worldwide Available from: http://globocan.iarc.frAccessed September 15, 2015
   Google Scholar
• StewartBWWildCPWorld Cancer Report 2014Lyon, FranceInternational Agency for Research on Cancer (IARC) – World Health Organization2014
   Google Scholar
• Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical OncologyJ Clin Oncol1997158299630189256144
   PubMed Web of Science ®Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• Le ChevalierTBrisgandDDouillardJYRandomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patientsJ Clin Oncol19941223603678113844
   PubMed Web of Science ®Google Scholar
• DepierreAChastangCQuoixEVinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trialAnn Oncol1994513742
   PubMedGoogle Scholar
• CrawfordJO’RourkeMSchillerJHRandomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancerJ Clin Oncol19961410277427848874339
   PubMed Web of Science ®Google Scholar
• WozniakAJCrowleyJJBalcerzakSPRandomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group studyJ Clin Oncol1998167245924659667264
   PubMed Web of Science ®Google Scholar
• Le ChevalierTBrisgandDSoriaJCLong term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancerOncologist20016suppl 1811
   PubMedGoogle Scholar
• ManegoldCChemotherapy for advanced non-small cell lung cancer: standardsLung Cancer200134suppl 2S165S17011720760
   PubMedGoogle Scholar
• ReckMPopatSReinmuthNMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3ii27ii39
   Google Scholar
• BesseBAdjeiABaasPPanel MembersESMO2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseAnn Oncol20142581475148424669016
   PubMed Web of Science ®Google Scholar
• FindlayMvon MinckwitzGWardleyAEffective oral chemotherapy for breast cancer: pillars of strengthAnn Oncol200819221222218006898
   PubMedGoogle Scholar
• TwelvesCGollinsSGrieveRSamuelLA randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorou-racil/leucovorin regimens in patients with advanced colorectal cancerAnn Oncol200617223924516344278
   PubMed Web of Science ®Google Scholar
• LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511101158996131
   PubMed Web of Science ®Google Scholar
• CassidyJDouillardJYTwelvesCPharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trialBr J Cancer20069481122112916622438
   PubMed Web of Science ®Google Scholar
• KerbelRSKamenBAThe anti-angiogenic basis of metronomic chemotherapyNat Rev Cancer20044642343615170445
   PubMed Web of Science ®Google Scholar
• TorimuraTIwamotoHNakamuraTMetronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaTransl Oncol20136551151924151531
   PubMedGoogle Scholar
• BocciGKerbelRSPharmacokinetics of metronomic chemotherapy: a neglected but crucial aspectNat Rev Clin Oncol2016131165967327184418
   PubMed Web of Science ®Google Scholar
• TanEHRolskiJGrodzkiTGlobal Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancerAnn Oncol20092071249125619276396
   PubMed Web of Science ®Google Scholar
• De LenaMDRamlauRHansenOPhase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLCLung Cancer200548112913515777980
   PubMedGoogle Scholar
• GrallaRJGatzemeierUGebbiaVHuberRO’BrienMPuozzoCOral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient managementDrugs200767101403141017600389
   PubMedGoogle Scholar
• JassemJKosmidisPRamlauROral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancerAnn Oncol200314111634163914581271
   PubMed Web of Science ®Google Scholar
• FreyerGDelozierTLichinisterMPhase II study of oral vinorelbine in first-line advanced breast cancer chemotherapyJ Clin Oncol2003211354012506167
   PubMed Web of Science ®Google Scholar
• BriasoulisEAravantinosGKouvatseasGDose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational studyBMC Cancer20131326323718900
   PubMed Web of Science ®Google Scholar
• CazzanigaMETorriVVillaFEfficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I–II VICTOR-1 studyInt J Breast Cancer201420147 Article ID 769790
   Google Scholar
• AddeoRSgambatoACennamoGLow-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancerClin Breast Cancer201010430130620705563
   PubMed Web of Science ®Google Scholar
• PallisAGChandrinosVPavlakouGA multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLCCancer Chemother Pharmacol20116761239124520697712
   PubMedGoogle Scholar
• DCTDNCINIHDHHSCancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, 20032006 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed December 19, 2016
   Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst2000923205216
   PubMed Web of Science ®Google Scholar
• GnoniASilvestrisNLicchettaAMetronomic chemotherapy from rationale to clinical studies: a dream or reality?Crit Rev Oncol Hematol2015951466125656744
   PubMed Web of Science ®Google Scholar
• GameiroSRCaballeroJAHodgeJWDefining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killingCancer Biother Radiopharm2012271233522316209
   PubMedGoogle Scholar
• TanakaHMatsushimaHNishibuAClausenBETakashimaADual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturationCancer Res200969176987699419706755
   PubMed Web of Science ®Google Scholar
• TagliamonteMPetrizzoJNapolitanoMA novel multi-drug metronomic chemotherapy significantly delays tumor growth in miceJ Transl Med2016145826911136
   PubMedGoogle Scholar
• BourgeoisHVermorkenJDarkGEvaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumoursCancer Chemother Pharmacol200760340741317541591
   PubMedGoogle Scholar
• KhayatDRixeOBrunetRPharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study designCancer Chemother Pharmacol200454319320515160284
   PubMed Web of Science ®Google Scholar
• KajitaJKuwabaraTKobayashiHKobayashiSCYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomesDrug Metab Dispos20002891121112710950859
   PubMed Web of Science ®Google Scholar
• GirardNJacouletPGainetMThird-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practiceJ Thorac Oncol20094121544154919884862
   PubMed Web of Science ®Google Scholar
• MassarelliEAndreFLiuDDA retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancerLung Cancer2003391556112499095
   PubMed Web of Science ®Google Scholar
• CameriniAPuccettiCDonatiSMetronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)BMC Cancer20151535925943747
   PubMed Web of Science ®Google Scholar
• KontopodisEHatzidakiDVarthalitisIA phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research GroupJ Chemother2013251495523433445
   PubMed Web of Science ®Google Scholar